Fate Therapeutics Company
Fate Therapeutics (Nasdaq: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer.
Investors
.png)
.png)
.png)
(Reupload).png)
.png)
Technology:
mHealth
Industry:
Genomic and Epigenominc Instabillity
Headquarters:
United States
Founded Date:
2007
Employees Number:
11-50
Funding Status:
IPO
Investors Number:
7
Total Funding:
$360.2M
Estimated Revenue:
$1M to $10M
Last Funding Type:
Post-IPO Equity
Register and Claim Ownership